-
Pope visits San Marino, before addressing Italian political gathering
-
Australia lead by 101 in 2nd Bangladesh Test as 18 wickets fall on day one
-
Trump tariffs heap up as Canada tries to curb US reliance
-
'Aura' battles leap from social media to Latin America streets
-
Australia lose three wickets after skittling Bangladesh for 64
-
US, Canada fail to reach trade pact to avert Trump tariffs
-
Bangladesh all out for 64 in 2nd Test after Starc masterclass
-
Sudan farms lie barren as El Nino leaves Nile banks dry
-
Odyssey effect: stars sell Greece to a new wave of US tourists
-
Arctic shipping a daunting prospect in hotly contested region
-
South Korea to send first container ship through Arctic route
-
In US, rare earths extracted from coal mine wastewater
-
Starc takes 5-11 to leave Bangladesh reeling in 2nd Test
-
Nakashima pounds Fritz, Bejlek beats Keys in Cincinnati upsets
-
Injured Rune withdraws from US Open
-
Canadian negotiator says 'more work to do' on US trade deal
-
Nakashima knocks out Fritz to reach Cincinnati semi-finals
-
'Solid' Clark takes solo lead at BMW Championship
-
Ukraine says 'cynical' Russian strike on shopping centre killed 16
-
Arteta hails Arsenal's desire after perfect start to title defence
-
TikTok to pay $400 mn settlement in US children's privacy case
-
Betis down Real Sociedad in La Liga opener
-
MLS fines Messi for striking an opponent
-
Mexican governor resumes job despite US drug charges
-
Gouiri double fires Marseille past Strasbourg in Ligue 1 opener
-
Arsenal rout Coventry to open Premier League season in style
-
Mavericks buy out Thompson, now reportedly bound for Heat
-
Giant-killer Bejlek overhauls Keys to reach Cincinnati semi-finals
-
England v Pakistan first Test: Three talking points
-
Man Utd agree deal for Brighton midfielder Baleba: reports
-
US, Canada push to seal trade deal as deadline nears
-
Werro wins Lausanne 800m, well off world record pace
-
One dead, three wounded after sword attack at Swedish high school
-
China mulls bid to host 2028 UN climate talks: sources
-
Ukraine says 'cynical' Russian strike on shopping centre killed 15
-
Jones becomes third Englishman to join Inter this summer
-
US Supreme Court allows White House ballroom construction for now
-
Mexican governor wanted on US drug charges returns to job
-
Root hails emerging fast bowlers as England thrash Pakistan
-
Bolivia's Paz forced to fire economy minister in mid-crisis
-
Brazil's Lula urges tariffs resolution in call with Trump
-
A-Rod ups T-Wolves stake in $4.5bn ownership change
-
Ukraine says 'cynical' Russian strike on shopping centre killed 14
-
UK court orders Prince Harry, others to pay Daily Mail initial £9.5mn
-
Heatwave-hit Europe logs over 30,000 excess summer deaths: first figures
-
'Grateful' ex-world champion Alaphilippe retires from cycling
-
Give LIV Golf 'one more shot,' says DeChambeau
-
US, Canada work to wrap up trade deal ahead of looming deadline
-
Duplantis hits the high notes for athletics anthem
-
Malaysia's JDT claim unbeaten run world record
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2026
DORADO, PR / ACCESS Newswire / June 15, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm today announced that revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year.
Net income for the three and six months ended April 30, 2026, was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.
"We are encouraged by our results for the quarter, particularly the improvement in profitability," said Mr. Sanchez, Chief Executive Officer. "Our continued strategic focus on markets that offer the greatest opportunities for return, combined with disciplined cost management and operational efficiency, contributed to the improved financial performance."
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries to Puerto Rico, United States, Europe and Brazil markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2025, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787-278-2709
SOURCE: Pharma-Bio Serv, Inc.
View the original press release on ACCESS Newswire
W.Nelson--AT